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The N-terminal head domain of human dystrophin has been expressed in soluble form and high yield in E. co/i. allowing us to test the previously 
unconfirmed assumption that dystrophin binds actin. DMD26. the first 246 amino acid residues of dystrophin. binds F-ah in a strongly 
co.operative manner with a Hill constant of 3.5, but does not bind G-actin, Dystrophin heads are thus I’unctionally competent aciinebinding proteins. 
This result opens the way to identifying critical residues in the actin-binding site and encourages us that the other domains of dystrophin might 
also be treated as functionally autonomous modules. accessible to a similar approach. 
Dystrophin: Actin.bindinp: Muscular dystrophy: Alpha-actinin 
1. INTRODUCTION 
Duchenne muscular dystrophy (DMD) and Becker 
muscular dystrophy (BMD) are X-linked human degen- 
erative muscle disorders [I]. Both arise from alterations 
in the dystrophin gene: DMD from a total absence of 
dystrophin and BMD from the expression of truncated 
forms [2]. The dystrophin molecule can be divided into 
four domains (I-IV) based on its amino acid sequence. 
The N-terminal domain (I) of the human isoform, con- 
taining -240 amino acids, is 44% identical to the F-actin 
binding domain of chick smooth muscle or-actinin and 
related cross-linking proteins [3-61. The major domain 
(II) comprises 25 repeating elements imilar to those in 
spectrin [6,7]. Deletions of up to 50% in domain II are 
responsible for the ‘Becker phenotypes [8]. suggesting 
that dystrophin can tolerate limited changes in structure 
and still retain partial function. Domain III is a cysteine 
rich region of -150 amino acids that contains two ‘EF- 
hand’ calcium-binding motifs, though the match to the 
consensus calcium-binding sites is poor [6]. Domain IV 
is a unique C-terminal domain of -420 amino acids [6] 
that associates with membrane glycoproteins and may 
provide membrane anchorage [9, IO]. 
Progress has been made in analyzing these dystro- 
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phies at the cytogenetic level [I 1.121, and antibodies 
have localized the protein in the sarcolemma [l3] as a 
component of the junctional folds [14]. However, very 
little is known about the biochemical properties, inter- 
actions and cellular functions of dystrophin. This is 
because it has not been possible to obtain adequate 
amounts of protein from muscle tissue for biochemical 
studies [9,14,15]. However, very small amounts of pure 
dystrophin have been prepared for electron microscopy 
[IS]: these confirmed the potential for self-association 
predicted from sequence studies [6]. In particular, actin- 
binding has yet to be unequivocally demonstrated, al- 
though NMR measurements u ing short synthetic N- 
terminal peptides of dystrophin arc suggestive [16]. 
Here WC have expressed omain 1 of human dystrophin 
in E. co/i and shown that it binds F-actin co-operatively 
with 50% binding occurring at 44 ,ctM. 
2. MATERIALS AND METHODS 
In the abscncc ofu crystal structure it is not possible to define the 
C-terminal end of domain I of dystrophin. Since prolinc residues tend 
to disrupt secondary structure, WC have chosen to dchnc the C-termi- 
nal boundary as residues 255-258 (Pro-Arg-Pro-Pro). Uased on this, 
the constructs DMD233. DMD246 and DMD254 (containintr the first 
233.246 and 254 residues ofdystrophin. respectively) were synthesized 
and exprctsscd in high yield (Fig. I), 
A clone. CF27. bp 410-2350 of the humandystrophincDNA, in the 
f3u~~tHI-k~coRI sites of pGEM3ZF+ was a generous gift from Drs. 
Kay Davies and Don Love (Molecular Genetics Group. Institute of 
Molecular Medicine, Jnhn Radcliffe Hospital, Oxford OX3 9DU. 
UK). The missing DNA sequence corresponding to the first 66 amino 
acids of dystrophin was assembled from 5 olipnucleotides whose 
codon usage was optimised for E. co/i expression. The resulting 207 
bp fragment (DMD68) from the oligonucleotidc annealing and Ii&a- 
tion reaction has a S’N&,l and a 3’fIurnHl site. To ligate DMD68 10 
the 5’ end of CFZ7 it was necessary to re-engineer a OuarHI site that 
PLib!ishcd by Eiscvier Sn’enc~ P~~bli.sArrs 6. V. 243 
Volume 301. number 3 FEBS LETTERS April 1992 
had been lost during the cloning of CF27 into pGEM3ZF+. A PCR 
reaction was used to generate a f?u~tHI site at lhe 5’ end of CF27 and 
to insert a TAG stop codon and Hind111 site after amino acid residue 
254 in dystrophin. The product of this reaction was ligated simultane- 
ously with DMD68 into the AkkI-Hi~ldlII sites of the pMW172 ex- 
pression vector. Colonies containing the correct construct (DMD254) 
were identified by PCR and restriction digestion. An Xiluf-Hi~tdtlf 
fragment of DMD254 was cloned into M I3mpl9 to confirm the Adel- 
ity of the construct by sequencing, DMD246 and DMD233 were 
produced by the insertion of a stop codon after residues 246 and 233. 
respectively, by PCR using DMD254 as template. All DMD pMW 172 
constructs were sequenced in M 13mpl9 before transformation i to 
BL2l(DE3) and expression. Details of the cloning, expression and 
purification methods were based on those used for gelsolin mutants 
[17,18]. 
F-actin binding was assessed using sedimentation at 20°C in a 
Beckman Airfuge with 13.9 PM actin in IO mM Tris-HC1, pH 8.0.0. I
M NaCI, I mM MgCl:, 0. I mM ATP, I ,O mM dithiothreitol and 3 mM 
NaN,, with either 0.1 mM CaCI, or 0.2 mM EGTA as described 
previously [191. Supernatant fractions were removed and the pellets 
redissolved inan equivalent volume of buffer for analysis on IS% SDS 
PAGE. Gels were scanned on a Molecular Dynamics computing den- 
sitometer, Control experiments using bovine serum albumin showed 
that 3.4% of the total albumin was trapped in the pellets. The bound 
dystrophin value was corrected for this level of trapping. 
3. RESULTS AND DISCUSSION 
DMD246 and DMD254 were purified from the solu- 
ble fraction on Whatman DE52 resin as described for 
Segment 1 of gelsonlin [17]. Gel filtration on S200 indi- 
cated that DMD246 was fully monomeric. DMD233 
was expressed only in htclusion bodies. We could not 
analyze this construct, because it was not possible to 
obtain soluble material using procedures that had previ- 
ously allowed gelsolin to be solubilized in a functional 
form [17,20]. 
Both DMD246 and DMD254 bound F-actin in a 
concentration-dependent manner, independent of cal- 
cium (Fig. 2). Binding was unaffected by pH in the 
range 6.5-8.0 and was specific for F-actin. There was no 
binding to G-actin nor any evidence for capping the 
barbed ends of filaments based on measurements of the 
critical concentration of actin in the presence or absence 
of 2 or 10 ,uM DMD254 (using pyrene-labelled actin 
[17]- data not shown). DMD246 shows maximal bind- 
ing (1:l) at a 4-5.fold molar excess over actin (Fig. 3). 
Even at a 10.fold excess, we were unable to reach this 
stoichiometry with DMD254, showing that this larger 
construct bound more weakly. 
Apparent dissociation constants were estimated 
based on the dystrophin concentration required to 
achieve 50% maximal binding. A value of -44 PM was 
obtained for DMD246 (Fig. 3). This is about an order 
of magnitude higher than the Kd for the F-actin binding 
domain of filamiu (K,, = 3 PM [21]). The actin-binding 
domain of a-actinin, which shows 62% amino acid se- 
quence similarity with dystrophin [S], has also been ex- 
pressed in E. co/i, and binds F-a&n with a Kd of4 ,zM 
(Way et al. 1992, submitted), a value similar to that of 
the single actin-binding site of filamin. This gives us 
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Fig. I. Lanes l-3 show a representative purification of DMD254. 
Lane I. total cell protein; lane 2, soluble fraction; lane 3, DMD254 
pooled fractions alter chromatography on Whatman DES2. Lanes 4 
and 5 show the supernalant and pellet fractions from control airfuge 
assays of DMD254 alone as described in Fig, 2 (there is negligible 
protein in the pellet). 
confidence that functional activity of these domains is 
preserved following expression in the bacterial system. 
It is evident from the sigmoidal nature of the binding 
plot that DMD246 associates with F-aciin in a strongly 
co-operative manner. lJsing non-linear egression to fit 
these data with the Hill Equation (with Entitter, dis- 
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Fig. 2. Supernatant (S) and pellet (P) fractions after centrifugation of 
mixtures of DMD246 with F-actin. The upper band is actin and the 
lower, DMD246. Proteins were mixed al molar ratios of 
DMD246:actin as follows: I = 06, 2 = 0.9, 3 = I .7, 4 = 2.6, 5 = 3.5, 
6 = 4.3, 7 = 5.2, 8 = 6.0, 9 = 7.0, IO = 7.8, Similar results were ob- 
tained in calcium. 
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Fig, 3. Binding of DMD246 (m) and DMD?W (2:) to F-actin in 
EGTA. Bound actin has been expressed as a molar ratio to F-actin 
subunits. Non-linear least squares fitting gives a Hill constant of 3.48. 
tributed by Biosoft, Cambridge, UK) gave a Hill con- 
stant of 3.48 ? 0.15. Co-operativity of binding to F- 
actin has been noted previously for both tropomyosin 
[22] and a-actinin f23]. In the former case this is due to 
end-to-end association of the tropomyosin molecules 
and in the latter to bundling of the actin filaments. In 
the case of the dystrophin, the co-operativity suggests 
self-association, possibly induced by binding to actin 
filaments. As stated above, there was no evidence for 
self-association of DMD246 from gel filtration (at least 
at concentrations up to -10 PM). Furthermore, the & 
of intact dystrophin may be even lower, if, as indicated 
from electron microscopy, distrophin dimerizes [151. 
For example, the apparent K,, for dissociation of the 
or-actinin dimer from actin is 0.4pM, IO-fold lower than 
our Kd for the actin-binding domain on its own. This 
shows the extent to which binding affinity is increased 
by cross-linking filaments. Finally, as in the case of the 
spectrin dimer whose affinity for actin is enhanced by 
several orders of magnitude in the presence of Band 4.1 
[24], additional components that bind to dystrophin, 
such as the glycoprotein complex [9], may also affect 
interaction with actin. 
Our results demonstrate conclusively that the puta- 
tive F-actin binding site of dystrophin indeed binds F- 
actin*. Although dystrophin constitutes only 0.002% of 
total muscle protein [25], its concentration in the mem- 
brane cytoskeleton fraction is very much greater (about 
5% [26]). Thus attachment of dystrophin to membrane 
sites in the sarcolemma increases its effective conccntra- 
tion over l,OOO-fold to > lOOpM. This high affinity for 
membranes may account for the lack of any association 
of dystrophin with stress fibres when expressed in COS 
cells [27]. From this it is clear that the local concentra- 
tions of both dystrophin and actiri are suficiently great 
that high ‘revels of binding arc expected to occur is! viva. 
*Qualitative demonstration of dystraphin binding to F-actin has rc. 
cently bbyn reported using a fusion protein containing the first 233 
rcsiducs of human dystrophin and ~utathione~S.transfcase (Hcm- 
mings. L.. Kuhlman, PA. and Critchlcy, D.R,, J, Cell Biol.. in press). 
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